Disease Study population Quantitative strategy MS approach Validation Major findings CAD with PTCA [78 ] CAD ( )
16 O/18 O and iTRAQ labeling, IEF and SCX seperationNano-LC- MS/MS None Protective properties of HDL might be impaired after PTCA ACS [98 ] ACS ( ), healthy ( ) 2D-DIGE MALDI-TOF-TOF ELISA Western blot Functional HDL subfractions shifted to dysfunctional HDL subfractions during ACS CAD [99 ] CAD ( ), ACS ( ), and healthy ( ) 1D-PAGE and label-free quantification (peptide index) Nano-LC-MS/MS ELISA IHC Western blot A reduced clusterin and increased apolipoprotein C-III content of HDL in CAD and ACS as mechanisms leading to altered effects on endothelial apoptosis Hemodialysis (HD) [79 ] HD ( ), healthy ( ) iTRAQ with IEF fractionation LC-MALDI-TOF ELISA Increase of apoCII/apoCIII and the decrease of serotransferrin in HDL of HD patients CAD ACS [80 ] Healthy ( ), CAD ( ), and ACS ( ) Label-free quantification (spectral counts and emPAI) Nano-LC-MS/MS Immunoblot or ELISA Increased abundance of SAA, C3, and other inflammatory proteins in HDL from ACS patients suggests that HDL reflects a shift to an inflammatory profile AMI [82 ] AMI ( ), FH ( ), and healthy ( ) 2D-PAGE MALDI-TOF ELISA Western blot TTR values are reduced in patients with high cardiovascular risk Uremia [81 ] ESRD ( ), healthy ( ), and CKD ( ) 1D-PAGE, label-free method with peptide index Nano-LC-MS/MS ELISA Western blot SAA in ESRD-HDL can promote inflammatory cytokine production CAD [8 ] CAD ( ), healthy ( ) MALDI-TOF peptide profiling MALDI-TOF-TOF MALDI-TOF Developed a MALDI-TOF pattern containing peptides from apoA-I (oxidation at Met (112)), apoC-III (upregulated), lipoprotein(a) (upregulated), and apoC-I (downregulated) to classify CAD and control subjects